一种STAT3降解剂在抗venetoclax的急性髓性白血病中显示出有效性
Samarpana Chakraborty1,2, Claudia Morganti2,3, Kimberly Zaldana4
1Montefiore Einstein Comprehensive Cancer Centre (MECCC), Bronx, NY, USA.
Leukemia
|February 17, 2026
概括
通过破坏线粒体,STAT3上调驱动急性髓性白血病 (AML) 中对venetoclax的耐药性. 一种新型的STAT3降解剂有效地向这种耐药性,显示出治疗耐药AML的前景.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 急性髓性白血病 (AML) 是一种具有不良结果的侵袭性癌症.
- 威尼托克拉克斯 (Ven) 是有前途的药物,但由于MCL1上调和线粒体问题,耐药性往往导致复发.
- 过度表达STAT3与低生存率和骨髓质恶性瘤有关.
研究的目的:
- 确定AML中venetoclax耐药性的机制.
- 为了研究STAT3在venetoclax耐药性的作用.
- 评估一种新型的STAT3降解剂作为治疗策略,用于治疗venetoclax耐药AML.
主要方法:
- 研究了对venetoclax耐药AML的STAT3上调调节.
- 在AML细胞系中使用了临床相关的STAT3降解剂.
- 在venetoclax耐药AML小鼠模型中测试了STAT3降解剂 (KT-333).
主要成果:
- 确定STAT3上调作为venetoclax耐药性的关键机制.
- STAT3降解剂降低了STAT3和MCL1水平,纠正了线粒体功能障碍,并在耐性AML细胞中诱导了亡.
- 在venetoclax耐药AML小鼠模型中,KT-333治疗改善了生存率.
结论:
- STAT3过活化是白血病引起的,并且在抗venetoclax的AML中被强化.
- 用一种新型降解剂向STAT3是一种有前途的治疗方法,用于抗药性髓状瘤.
- STAT3抑制间接下调MCL1,为AML和MDS中抗性克隆提供了一种策略.
更多相关视频
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
11.2K
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
980
相关概念视频
01:10Drugs that Destabilize Microtubules
4.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.0K
01:29Venous Thrombosis III: Interprofessional Care
388
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
388